Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FF/VI once daily versus salmeterol/fluticasone propionate twice daily in COPD
2010-021059-25Phase 3Completed
- Sponsor
- GSK
- Start
- Nov 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of fluticasone, vilanterol, salmeterol and fluticasone propionate in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Change from baseline in 24-hour weighted mean serial trough FEV1 at Day 84. Started Nov 2010; status: completed.
02
Drugs
fluticasonevilanterolsalmeterolfluticasone propionate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2010-021059-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021059-25.